BMI, Mortality, and Cardiovascular Outcomes in Type 1 Diabetes: Findings Against an Obesity Paradox
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Low weight has been associated with increased mortality risks in type 1 diabetes. We aimed to investigate the importance of weight and weight gain/loss in the Swedish population diagnosed with type 1 diabetes. RESEARCH DESIGN AND METHODS: Patients with type 1 diabetes (n = 26,125; mean age 33.3 years; 45% women) registered in the Swedish National Diabetes Registry from 1998 to 2012 were followed from the first day of study entry. Cox regression was used to calculate risk of death from cardiovascular disease (CVD), major CVD events, hospitalizations for heart failure (HF), and total deaths. RESULTS: Population mean BMI in patients with type 1 diabetes increased from 24.7 to 25.7 kg/m2 from 1998 to 2012. Over a median follow-up of 10.9 years, there were 1,031 deaths (33.2% from CVD), 1,460 major CVD events, and 580 hospitalizations for HF. After exclusion of smokers, patients with poor metabolic control, and patients with a short follow-up time, there was no increased risk for mortality in those with BMI <25 kg/m2, while BMI >25 kg/m2 was associated with a minor increase in risk of mortality, major CVD, and HF. In women, associations with BMI were largely absent. Weight gain implied an increased risk of mortality and HF, while weight loss was not associated with higher risk. CONCLUSIONS: Risk of major CVD, HF, CVD death, and mortality increased with increasing BMI, with associations more apparent in men than in women. After exclusion of factors associated with reverse causality, there was no evidence of an obesity paradox.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
External review and validation of the Swedish national inpatient register
Ludvigsson, J. F., Andersson, E., Ekbom, A., Feychting, M., Kim, J.-L., Reuterwall, C., Heurgren, M., & Olausson, P. O. (2011) · BMC Public Health · doi:10.1186/1471-2458-11-450 · Cited by 5,055 · cited 1×
“Through the personal identity number assigned to all Swedish residents (12), we linked the following Swedish national registers: the NDR; Inpatient Registry (IPR), which is part of the National Patient Register (13); the Cause of Death Registry; and the Longitudinal Database for Health Insurance and Labor Market.”
BackgroundStandards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Glycemic Control and Excess Mortality in Type 1 Diabetes
Lind, M., Svensson, A.-M., Kosiborod, M., Gudbjörnsdottir, S., Pivodic, A., Wedel, H., Dahlqvist, S., Clements, M., & Rosengren, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408214 · Cited by 964
Self-citationRawshani, A., Sattar, N., Franzén, S., Rawshani, A., Hattersley, A. T., Svensson, A.-M., Eliasson, B., & Gudbjörnsdottir, S. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31506-x · Cited by 802
Self-citationEmpagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials
Rosenstock, J., Marquard, J., Laffel, L. M., Neubacher, D., Kaspers, S., Cherney, D. Z., Zinman, B., Skyler, J. S., George, J., Soleymanlou, N., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1749 · Cited by 363 · cited 1×
“Similarly, there is ongoing work investigating the benefits of adjunct sodium–glucose cotransporter 2 inhibitors in type 1 diabetes (19).”
BackgroundTemporal patterns in overweight and obesity in type 1 diabetes
Conway, B., Miller, R. G., Costacou, T., Fried, L., Kelsey, S., Evans, R. W., & Orchard, T. J. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.02956.x · Cited by 326 · cited 1×
“Also, the prevalence of obesity in the general Swedish population has increased steadily over past decades (3), and for patientswith type 1 diabetes, weight gain is a potential side effect of intensive insulin therapy, which is the mainstay of modern management (4).”
BackgroundReverse Causality in Cardiovascular Epidemiological Research: More Common Than Imagined?
Sattar, N., & Preiss, D. (2017) · Circulation · doi:10.1161/circulationaha.117.028307 · Cited by 211
Self-citationPurnell, J. Q., Braffett, B. H., Zinman, B., Gubitosi-Klug, R. A., Sivitz, W., Bantle, J. P., Ziegler, G., Cleary, P. A., Brunzell, J. D., DCCT/EDIC Research Group, et al. (2017) · Diabetes Care · doi:10.2337/dc16-2523 · Cited by 120
Hero, C., Rawshani, A., Svensson, A.-M., Franzén, S., Eliasson, B., Eeg-Olofsson, K., & Gudbjörnsdottir, S. (2016) · Diabetes Care · doi:10.2337/dc15-2450 · Cited by 78
Self-citation
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Obesity cardiomyopathy: evidence, mechanisms, and therapeutic implications
Ren, J., Wu, N. N., Wang, S., Sowers, J. R., & Zhang, Y. (2021) · Physiological Reviews · doi:10.1152/physrev.00030.2020 · Cited by 370
Shah, V. N., Peters, A. L., Umpierrez, G. E., Sherr, J. L., Akturk, H. K., Aleppo, G., Bally, L., Cengiz, E., Cinar, A., Dungan, K., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241291512 · Cited by 36
“38 The mechanisms underlying increased obesity in people with T1D are likely to be similar to those that apply to the population without diabetes, such as influx of energy-dense foods, sedentary behavior, and socioeconomic factors such as food insecurity.”
Schmidt, S., Frandsen, C. S., Dejgaard, T. F., Vistisen, D., Halldórsson, T., Olsen, S. F., Jensen, J. B., Madsbad, S., Andersen, H. U., & Nørgaard, K. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14567 · Cited by 29
Xu, Y., Echouffo Tcheugui, J. B., Coresh, J., Grams, M. E., Selvin, E., Fang, M., & Shin, J. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16300 · Cited by 15
Clinical potential of fasting in type 1 diabetes
Varady, K. A., Runchey, M.-C., Reutrakul, S., Vidmar, A. P., & Chow, L. S. (2024) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2024.01.007 · Cited by 12
Drawing lines in the sand: The growing threat of obesity in type 1 diabetes
Koufakis, T., Patoulias, D., Zografou, I., Papanas, N., & Popovic, D. S. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i5.823 · Cited by 10
Metadata
- Authors
- Edqvist, J., Rawshani, A., Adiels, M., Björck, L., Lind, M., Svensson, A.-M., Gudbjörnsdottir, S., Sattar, N., & Rosengren, A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-05-02
- Volume
- 42
- Issue
- 7
- Pages
- 1297-1304
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2942746363
- Cited by
- 99
- References
- 10
- FWCI
- 6.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.